Mitogen-activated protein kinases (MAPKs) are activated through the kinase cascades of MAPK, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). MAPKKKs phosphorylate and activate their downstream MAPKKs, which in turn phosphorylate and activate their downstream MAPKs. MAPKKK proteins relay upstream signals through the MAPK cascades to induce cellular responses. However, the molecular mechanisms by which given MAPKKKs are regulated remain largely unknown. Here, we found that serine-threonine protein kinase 38, STK38, physically interacts with the MAPKKKs MEKK1 and MEKK2 (MEKK1/2). The carboxy terminus, including the catalytic domain, but not the amino terminus of MEKK1/2 was necessary for the interaction with STK38. STK38 inhibited MEKK1/2 activation without preventing MEKK1/2 binding to its substrate, SEK1. Importantly, STK38 suppressed the autophosphorylation of MEKK2 without interfering with MEKK2 dimer formation, and converted MEKK2 from its phosphorylated to its nonphosphorylated form. The negative regulation of MEKK1/2 was not due to its phosphorylation by STK38. On the other hand, stk38 short hairpin RNA enhanced sorbitolinduced activation of MEKK2 and phosphorylation of the downstream MAPKKs, MKK3/6. Taken together, our results indicate that STK38 negatively regulates the activation of MEKK1/2 by direct interaction with the catalytic domain of MEKK1/2, suggesting a novel mechanism of MEKK1/2 regulation.
Introduction
The mitogen-activated protein kinase (MAPK) cascades, in which the major components are MAPK, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK), are conserved in eukaryotic cells (Cano and Mahadevan, 1995; Herskowitz, 1995; Waskiewicz and Cooper, 1995; Chang and Karin, 2001 ). In mammals, three major groups of MAPKs have been characterized: the extracellular signal-regulated protein kinases (Cobb and Goldsmith, 1995; Marshall, 1995) , the c-Jun NH 2 -terminal kinases (JNK; Kyriakis et al., 1994; Gupta et al., 1996) and the p38 kinases (Han et al., 1994; Enslen et al., 1998) . The extracellular signal-regulated protein kinases cascade is mostly activated by agonists of tyrosine kinase-encoded receptors and G protein-coupled receptors that induce mitogenesis or differentiation (Cobb and Goldsmith, 1995; Marshall, 1995) , whereas the JNK and p38 cascades are strongly activated by proinflammatory cytokines or extracellular stresses (Davis, 2000; Kyriakis and Avruch, 2001) .
MAPKKKs phosphorylate and activate MAPKKs, which in turn phosphorylate MAPKs. There is increasing evidence from biochemical and genetic analyses that the MAPKKKs link a variety of extracellular stimuli to cytoplasmic and nuclear effectors by activating downstream MAPK pathways. In addition, overexpression of many MAPKKKs could also activate the IkB kinase NF-kappaB pathway (Karin and Ben-Neriah, 2000; Yang et al., 2001) . MEKK1 is the first MAPKKK to be identified based on its homology with the Saccharomyces cerevisiae MAPKKK STE11 (Lange-Carter et al., 1993) . MEKK1 was initially discovered as an MAPKKK for the extracellular signal-regulated protein kinases pathway (Lange-Carter et al., 1993) . However, subsequent studies indicated that it preferentially activates the JNK pathway (Minden et al., 1994; Yan et al., 1994; Davis, 2000) . The amino-terminal regulatory domain of MEKK1 has been suggested to interact with other proteins, such as 14-3-3 (Fanger et al., 1998) . The carboxy-terminal region of MEKK1 contains a catalytic domain that binds and phosphorylates SEK1 (Xia et al., 1998) . MEKK1 protects cells from apoptosis, and contributes to cell migration (Minamino et al., 1999; Yujiri et al., 2000) . MEKK2 belongs to the MEKK/STE11 subfamily, which are widely expressed and potent activators of the NF-kB and MAPK pathways (Blank et al., 1996) . MEKK2 has a catalytic domain in its carboxyl-terminal region (Blank et al., 1996) , and is activated by forming a dimer (Cheng et al., 2005a) . MEKK2 has been suggested to be involved in T-cell-receptor signaling (Su et al., 2001; Guo et al., 2002) and was shown to regulate cytokine gene expression (Chayama et al., 2001; Kesavan et al., 2004) . However, it is still largely unknown how MEKK1, MEKK2 and other MAPKKKs are activated.
Serine-threonine protein kinase 38 (STK38)/NDR1 (GenBank accession number NP009202) is a serine/ threonine protein kinase belonging to a subclass of the AGC family of protein kinases (Manning et al., 2002; Tamaskovic et al., 2003; Hergovich et al., 2006) , which includes cyclic AMP-dependent kinase, protein kinase B and protein kinase C. The NDR family is highly conserved; it includes the mammalian STK38/NDR1 and STK38L/NDR2, Drosophila melanogaster TRC, Schizosaccharomyces pombe Orb6 and Saccharomyces cerevisiae Cbk1 and Dbf2 (Manning et al., 2002; Tamaskovic et al., 2003) . Of these, Cbk1 and Orb6 are involved in regulating cell morphology (Verde et al., 1998; Bidlingmaier et al., 2001) , and Dbf2 is a cell cycleregulated kinase, the activity of which is required for progression through anaphase (Johnston et al., 1990) . Despite these intriguing observations, STK38/NDR1 has no known natural substrates and has not been implicated in the MAPK signal transduction pathway.
Previously, we reported the isolation of a radioresistant mutant with low JNK activity from the human T-cell leukemia cell line MOLT-4 (Enomoto et al., 2000) . We then compared the gene expression profile of this mutant with that of the parental MOLT-4 cells using a DNA microarray system to elucidate the mechanism underlying the modulation of stress signaling. Our previous study demonstrated that X-irradiation induced downregulation of c-myc in MOLT-4 but did not in the radio-resistant mutant cells (Enomoto et al., 2003) . To further study, we constructed expression vectors encoding the genes that were significantly overexpressed in the radio-resistant cells, transfected them into 293T cells, and analysed their ability to modulate JNK signaling and to bind components of the JNK cascade. Among these gene products, we identified STK38 as an inhibitor of MEKK1 and MEKK2 (MEKK1/2), which are MAPKKKs that function in the MAPK cascades.
Here we show that STK38 physically interacts with MEKK1/2, and that overexpression of STK38 leads to reduced MEKK1/2 activity. In contrast, stk38-specific short hairpin RNA (shRNA) enhanced sorbitol-induced activation of MEKK2 and subsequent phosphorylation of the downstream MAPKKs, MKK3/6. Our findings indicate that STK38 functions as a negative regulator of MEKK1/2 in vivo, and does so, at least for MEKK2, by inhibiting its autophosphorylation.
Results

Expression and localization of STK38
We generated a polyclonal antibody against a portion of human STK38, and investigated STK38 expression in various cell lines by western blotting. STK38 was expressed in all the cell lines examined, including HeLa, 293T, MCF-7 and MOLT-4 (Figure 1a) . Previously, we reported the isolation of a radio-resistant mutant cell line with lower than normal JNK activity, Rh-1a, derived from MOLT-4 cells (Enomoto et al., 2000) . We then found that the expression level of stk38 mRNA was upregulated in Rh-1a cells as compared with the parental MOLT-4 cells by DNA microarray analysis (data not shown); the STK38 protein was also upregulated in the Rh-1a line ( Figure 1a) . Next, to determine the subcellular localization of STK38, we performed subcellular fractionation of 293T cells and subjected each fraction to western blotting with the anti-STK38 antibody. Figure 1b shows that STK38 localized to the cytoplasm.
STK38 interacts with MAPKKK but with neither MAPKK nor MAPK in the JNK cascade
We then examined the possible involvement of STK38 in the JNK signaling pathway. First, the binding specificities The expression of STK38 protein examined by the western blotting of total proteins isolated from various cell lines probed with a polyclonal antibody to STK38. The Rh-1a cell line is a radioresistant mutant derived from MOLT-4 cells. (b) Localization of STK38 in cells. Subcellular fractionation was performed using 293T cells, and each fraction was subjected to western blotting with the indicated antibodies. MEK1, Bcl-2 and Sp-1 were positive controls for cytosolic, mitochondrial and nuclear protein, respectively. STK38, serine-threonine kinase 38.
Inhibition of MEKK1/2 by STK38
A Enomoto et al of STK38 for various components of the JNK cascade were examined in co-transfection experiments. We transiently expressed V5-tagged full-length STK38 with Xpress epitope-tagged JNK1, FLAG-SEK1, or FLAG-MEKK1 in 293T cells. The STK38-V5 proteins were recovered from cell extracts by immunoprecipitation, and the precipitates were examined for JNK cascade components by western blotting with anti-Xpress or anti-FLAG antibody. The results showed that STK38 interacted with MEKK1, but no binding was detected with either JNK1 or SEK1 (Figures 2a-d) . We further examined whether STK38 bound other MAPKKKs, and found that STK38 also interacted with MEKK2 ( Figure 2e) . Next, the physical interaction between STK38 and MEKK1/2 was evaluated. Endogenous STK38 was immunoprecipitated from HeLa cells using anti-STK38 serum. The immunoprecipitates were subjected to western blotting with anti-MEKK1 antibody. The results showed that STK38 physically interacted with MEKK1 (Figure 2f, top) . Western blotting analysis of the MEKK2 immunoprecipitates using anti-STK38 antibody indicated that MEKK2 also physically associated with STK38 (Figure 2f, bottom) . Moreover, we investigated the effects of extracellular stimuli on STK38 kinase activity and on the interaction between MEKK2 and STK38. Exposure of 293T cells to sorbitol or anisomycin did not modulate the STK38 kinase activity or the binding activity of MEKK2 to STK38 (Supplementary Figure 1 and data not shown).
STK38 inhibits the activities of MEKK1 and MEKK2
Expression of full-length MEKK1 or MEKK2 by transient transfection in cells leads to their auto-activation and the subsequent activation of the stress-activated protein kinase cascades, also known as the JNK and p38 cascades (Minden et al., 1994; Yan et al., 1994; Blank et al., 1996; Cheng et al., 2000) . To investigate the possible effects of STK38 on the stress-activated protein kinase signaling pathway, we first examined whether MEKK1-induced SEK1 phosphorylation was influenced by the co-transfection of STK38 in 293T cells. Overexpression of full-length MEKK1 induced a marked increase in endogenous SEK1 phosphorylation, and the co-transfection of STK38 inhibited MEKK1-induced SEK1 phosphorylation in a dose-dependent manner ( Figure 3a) . We next examined the effects of a kinaseinactive mutant STK38 (K118A) on MEKK1-induced SEK1 phosphorylation; this construct, STK38 (K118A), had a point mutation in the catalytic site at residue Lys-118, and had no STK38 kinase activity ( Figure 3b ). The expression of kinase-inactive STK38 (K118A) did not fully inhibit MEKK1-induced phosphorylation of endogenous SEK1 (Figure 3c ). To confirm that STK38 is a negative regulator of MEKK1, we examined the ability of MEKK1 to phosphorylate glutathione S-transferase (GST)-SEK1 (K129R) in the presence or absence of STK38. Consistent with the results for endogenous SEK1 phosphorylation, wild-type STK38 inhibited the MEKK1 activity but STK38 (K118A) did not (Figure 3c , bottom). Moreover, we examined the role of STK38 in MEKK2 signaling. Overexpression of STK38 significantly suppressed MEKK2 activity and MEKK2-mediated phosphorylation of endogenous SEK1 or MKK7, another downstream target of MEKK2. However, STK38 (K118A) failed to suppress MEKK2 activation ( Figure 3d ). We further investigated whether STK38 is involved in the p38 signaling pathway. Transfection of full-length MEKK1 into 293T cells caused the phosphorylation of p38, and this phosphorylation was weakly inhibited by STK38 (Figure 3f ).
STK38 interacts with the catalytic domain of MEKK1 and MEKK2, and inhibits DMEKK1-induced SEK1 phosphorylation To define the region of MEKK1 responsible for its interaction with STK38, a series of FLAG-tagged or (f) STK38 physically interacts with MEKK1 and MEKK2. Cell lysates from HeLa cells were subjected to immunoprecipitation with rabbit pre-immune serum (Pre), anti-STK38 serum, antirabbit immunoglobulin G or anti-MEKK2 antibody. The immunoprecipitates were analysed by western blotting with anti-MEKK1 (top) or anti-STK38 antibody (bottom). STK38, serine-threonine kinase 38.
Inhibition of MEKK1/2 by STK38
A Enomoto et al HA-tagged MEKK1 deletion mutants were co-transfected along with V5-tagged STK38 into 293T cells. A co-immunoprecipitation study showed that STK38 interacted with the catalytic domain in the carboxy terminus of MEKK1, termed DMEKK1, but not with the amino-terminal region (Figures 4a and b) . The reciprocal experiment confirmed the interaction between STK38 and the catalytic domain of MEKK1 (Figure 4c ). STK38 also associated with the carboxy-terminal region of MEKK2, termed DMEKK2 (Figure 4d ). On the other hand, we investigated the binding region of STK38 involved in the interaction with MEKK1. We found that the region encompassing amino acids 87-465 of STK38, which encodes the catalytic domain, was co-immunoprecipitated with MEKK1 (Supplementary Figure 2b) . Thus, the amino-terminal region of STK38 is not required for the interaction with MEKK1. The carboxy terminus of MEKK1 is necessary for its interaction with SEK1 (Xia et al., 1998) . Therefore, we examined whether STK38 interfered with MEKK1-SEK1 complex formation. HAtagged DMEKK1 (KM), a MEKK1 mutant in which the catalytic domain in the COOH terminus was inactive, was introduced into 293T cells along with FLAG-SEK1 with or without STK38-V5. A co-immunoprecipitation study showed that DMEKK1 (KM) interacted with SEK1 and this interaction was not disrupted by STK38 (Figure 4e ). Transfection of cell lines with DMEKK1, an active form of MEKK1, activated the JNK pathway (Yan et al., 1994) . 293T cells were co-transfected with FLAG-MEKK1 (a, c, e) or FLAG-MEKK2 (d) alone or with STK38-V5 or STK38 (K118A)-V5. The cell lysates were subjected to immunoprecipitation with anti-FLAG antibody or western blotting with the indicated antibodies. The immunoprecipitates were analysed for MEKK1/2 activity by immune complex kinase assay (KA) with GST-SEK1 (KR) as the substrate. FLAG-MEKK2 showed two major bands: the faster and slower migrating bands are indicated by arrows. (b) STK38 kinase assay. 293T cells were transfected with the mock control, STK38-V5 or STK38 (K118A)-V5. The cell lysates were subjected to immunoprecipitation with anti-V5 antibody and the resultant immunoprecipitates were analysed for STK38 kinase activity by immune complex kinase assay with a synthetic peptide as the substrate. STK38 activity was measured with a liquid scintillation counter. The data are representative of three independent experiments. STK38, serine-threonine kinase 38.
Inhibition of MEKK1/2 by STK38 A Enomoto et al
We then examined the effects of STK38 on DMEKK1-induced SEK1 phosphorylation. As shown in Figure 4f , wild-type STK38 inhibited the phosphorylation of endogenous SEK1 by DMEKK1. The kinase-inactive mutant STK38 (K118A) partially suppressed DMEKK1-induced SEK1 phosphorylation, however, the effect was weak and was significantly different from that of wild-type STK38.
STK38 converts MEKK2 from its phosphorylated to its nonphosphorylated form and inhibits MEKK2 autophosphorylation When transiently expressed, full-length MEKK2 displayed multiple protein bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 5a ). Interestingly, co-transfection with STK38 significantly reduced the bands showing slower mobility and increased the faster migrating bands of MEKK2. Following treatment with a protein phosphatase or transfection with a kinase-inactive MEKK2 mutant such as MEKK2 (KM) alone or with STK38, only the faster migrating bands were observed. Therefore, the slower migrating bands of MEKK2 were phosphorylated species and the faster migrating bands were nonphosphorylated or hypo-phosphorylated species, suggesting that STK38 converts MEKK2 from its phosphorylated to its nonphosphorylated form. MEKK2 undergoes autophosphorylation, which is required for its activity (Cheng et al., 2005a) . Thus, we investigated the effect of STK38 on the autophosphorylation of MEKK2. GST-tagged MEKK2 or the MEKK2 (KM) mutant was mixed with an equivalent amount of immunopurified STK38 in the presence of [g-32 P]ATP to quantify the kinase reaction. As shown in Figure 5b , wild-type MEKK2 underwent autophosphorylation, but MEKK2 (KM) did not. The 32 P incorporated by wild-type MEKK2 was significantly decreased to 50% of the control levels by co-expression of wild-type STK38, indicating that STK38 significantly inhibited MEKK2 autophosphorylation activity. On the other hand, MEKK2 autophosphorylation was only weakly suppressed by the kinase-inactive mutant STK38 (K118A). These results indicate that STK38 inhibits MEKK2 activation by suppressing its autophosphorylation.
MEKK2 can form dimers in the presence of STK38 but is not a substrate for STK38 MEKK2 forms a dimer, leading to its activation through transphosphorylation (Cheng et al., 2005a) . As STK38 appeared to act as a negative regulator of MEKK2, one possibility was that STK38 interacted with the dimerization motif, preventing MEKK2 from forming a dimer, and hence inhibiting its activation. To assess this possibility, we co-transfected cells expressing FLAG-MEKK2 with Xpress-MEKK2 in the absence or presence of STK38-V5, and the cell lysates were immunoprecipitated with an anti-FLAG antibody. As shown in Figure 6a , Xpress-MEKK2 was co-precipitated by FLAG-MEKK2, indicating that MEKK2 formed dimers. The dimer formation of MEKK2 was not inhibited by co-expression of STK38, indicating that the binding domain of MEKK2 for STK38 is different from the dimerization motif. Indeed, a co-immunoprecipitation assay indicated that MEKK2 with deletion of the dimerization motif (342-424) still interacted with STK38 ( Supplementary  Figure 2a) . To determine whether the inhibitory action of STK38 on MEKK2 activity is mediated by STK38-catalysed MEKK2 phosphorylation, we immunopurified STK38-V5 from 293T cells and performed an in vitro STK38 kinase assay using GST-MEKK2 (KM) as a Figure 5 STK38 converts MEKK2 from its phosphorylated to its nonphosphorylated form and inhibits the autophosphorylation of MEKK2. (a) STK38 converts MEKK2 from its phosphorylated to its nonphosphorylated form. 293T cells were transfected with FLAG-wild-type MEKK2 or FLAG-MEKK2 (KM) alone, or with STK38-V5. The cell lysates were subjected to western blotting analysis with anti-FLAG or anti-V5 antibody. For calf intestine phosphatase (CIAP) treatment, the cell lysates were incubated with or without CIAP at 301C for 30 min before western blotting analysis. (b) STK38 inhibits MEKK2 autophosphorylation. In vitro kinase reaction was performed by incubating GST-MEKK2 alone or with the immunopurified wild-type STK38-V5 or STK38 (K118A)-V5 from the transfected 293T cells. The kinase reaction products were subjected to autoradiography (upper). The autophosphorylation activity of MEKK2 was measured using a phosphoimaging device and the results are shown as a bar graph. The data are representative of three independent experiments. Expression of GST-MEKK2 or STK38-V5 was confirmed by western blotting analysis using anti-GST or anti-V5 antibody, respectively. STK38, serine-threonine kinase 38; WB, western blotting; GST, glutathione S-transferase.
Inhibition of MEKK1/2 by STK38
A Enomoto et al substrate. Autophosphorylation of GST-wild-type MEKK2 was observed in the absence of STK38. However, direct phosphorylation of GST-MEKK2 (KM) or GST-DMEKK1 (KM) by STK38 was not detected (Figure 6b and data not shown). These results indicate that MEKK1 or MEKK2 is not a substrate for STK38.
Knockdown of STK38 enhances sorbitol-induced endogenous MEKK2 activation
To confirm that STK38 acts as a negative regulator of MAPKKK, we constructed an stk38 shRNA expression vector. As shown in Figure 7 , transfection with the stk38 shRNA, but not the control expression vector, specifically knocked down expression of the endogenous STK38 protein in HeLa cells ( 
Discussion
MAPKKKs respond to various upstream stimuli and activate multiple MAPK signaling components. However, Figure 6 MEKK2 forms dimers in the presence of STK38 but is not a substrate for STK38. (a) STK38 does not interfere with MEKK2 dimer formation. 293T cells were co-transfected with FLAG-MEKK2 and Xpress-MEKK2 in the absence or presence of STK38-V5. The cell lysates were subjected to immunoprecipitation using anti-FLAG antibody. MEKK2 dimer formation was evaluated by detecting Xpress-MEKK2 in the FLAG-immunoprecipitates by western blotting. (b) MEKK2 is not a substrate of STK38. 293T cells were transfected with STK38-V5 or STK38 (K118)-V5. The cell lysates were subjected to immunoprecipitation with anti-V5 antibody. The immunoprecipitates were analysed for STK38 kinase activity by immune complex kinase assay (KA) with GST-MEKK2 (KM) as the substrate. The kinase reaction products were subjected to SDS-PAGE and analysed by autoradiography. STK38, serine-threonine kinase 38.
Figure 7
Knockdown of STK38 enhances sorbitol-induced MEKK2 activation. HeLa cells were transfected with the negative control (C) or stk38-specific shRNA (S) expression vector. At 60 h after transfection, the cells were treated with 0.2 M sorbitol for 1 h or left untreated as controls and harvested. The cell lysates were subjected to immunoprecipitation with anti-MEKK2 antibody or western blotting with the indicated antibodies. The immunoprecipitates were analysed for MEKK2 activity by immune complex kinase assay (KA) with GST-SEK1 (KR) as the substrate. MEKK2 activity was measured using a phosphoimaging device and the results are shown as a bar graph. The data are representative of three independent experiments. STK38, serine-threonine kinase 38; shRNA, short hairpin RNA.
Inhibition of MEKK1/2 by STK38
A Enomoto et al it remains largely unclear how each MAPKKK is activated and which molecules regulate each MAPKKK. The overexpression of most MAPKKKs activates MAPK signaling pathways in mammalian cells (Yan et al., 1994; Blank et al., 1996) . The results of these transfection studies suggest that MAPKKKs may normally be negatively regulated by inhibitors or intracellular compartmentalization.
The results of the present co-transfection studies demonstrated that the STK38 interacts with MEKK1/2, but not with either SEK1 or JNK1. We also showed that STK38 physically interacts with MEKK1/2 in vivo. The carboxy-terminal region, but not the amino-terminal region, of MEKK1 or MEKK2 was required for binding STK38. The carboxy terminus of MEKK1 is necessary for its interaction with SEK1 (Xia et al., 1998) . A recent study demonstrated that GST M1-1 functions as a negative regulator of MEKK1 by interfering with the binding of MEKK1 to SEK1 (Ryoo et al., 2004) . However, STK38 did not interfere with the MEKK1/SEK1 complex formation, suggesting that STK38 inhibits MEKK1 in a manner distinct from that of GST M1-1. The carboxy terminus of MEKK2 is necessary for the dimer formation (Cheng et al., 2005a) . However, we showed that the dimerization motif of MEKK2 was not required for the interaction with STK38.
Full-length MEKK1 or MEKK2 was activated when overexpressed in 293T cells. Co-expression of MEKK1/ 2 with STK38 decreased the MEKK1/2 activity and inhibited phosphorylation of the downstream SEK1 or MKK7. MEKK1 also activates the MKK3/6-p38 signaling pathways (Lin et al., 1995) . As expected, overexpression of STK38, at least partially, inhibited the MEKK1-induced phosphorylation of p38. Recent studies have indicated that MEKK2 can undergo autophosphorylation and activation through dimer formation (Cheng et al., 2005a) and that Mip1, a MEKK2-interacting protein, inhibits MEKK2 activation by preventing its dimer formation (Cheng et al., 2005b) . However, we demonstrated that STK38 inhibits the autophosphorylation of MEKK2 in vitro and suppresses the activation of MEKK2 without interfering with its dimer formation in a transient transfection assay. In addition, MEKK1 activity is regulated by autophosphorylation (Deak and Templeton, 1997) . Thus, STK38 may inhibit the activation of MEKK1 by interfering with its autophosphorylation.
STK38 is a serine-threonine protein kinase that belongs to a subfamily of the AGC family of kinases (Manning et al., 2002) . However, natural substrates for STK38 have not been reported. It is possible that the inhibitory action of STK38 on MEKK2 activity is mediated by STK38-catalysed MEKK2 phosphorylation. However, our results indicated that MEKK2 is not a substrate for STK38 in vitro. These results suggest that MEKK1/2 activation is not inhibited through direct phosphorylation by STK38. On the other hand, the binding activity of STK38 (K118A) to MEKK1/2 was similar to that of wild-type STK38 (data not shown), suggesting that the kinase activity of STK38 may be necessary for inhibition of the activation of MEKK1/2. This raises the question of how STK38 regulates the activity of MEKK1/2. The kinase activity of STK38 may be necessary to recruit a negative regulator, such as a protein phosphatase, to MEKK1/2 and activate it, or STK38 may negatively regulate a putative activator of MEKK1/2, such as an MAPKKK kinase. Alternatively, it is possible that STK38 binds to the catalytic domain of MEKK1/2, disrupting its proper conformation for autophosphorylation.
Although the results of the present study established that STK38 functions as a negative regulator of MEKK1/2 signaling, it is likely that STK38 is also a critical regulator of MEKK3 as the STK38-binding motif in MEKK2 is conserved between MEKK2/3. Knockdown of STK38 by transfection with an STK38-specific shRNA expression vector enhanced sorbitol-induced activation of MEKK2 and subsequent phosphorylation of the downstream MAPKKs, MKK3/6. Taken together, our findings support the suggestion that STK38 is a natural negative regulator of MAPKKK, including at least MEKK1/2 and perhaps also MEKK3.
Materials and methods
Cell culture, transfection, and subcellular fractionation HEK293T, HeLa, MCF-7, and COS-7 cells were cultured in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (Hyclone, South Logan, UT, USA) and 1% penicillin/streptomycin (Sigma). MOLT-4 cells and the derivatives were grown in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin. For DNA transfection, the cells were plated, grown for 24 h, and transfected for 24-48 h with the appropriate expression vectors using FuGENE 6 (Roche, Mannheim, Germany). Empty pcD 3.1 vector was used to keep the total amount of DNA equivalent for each transfection. Subcellular fractionation was performed using a ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, Darmstadt, Germany).
Antibodies
A polyclonal antibody against human STK38 was generated by injecting rabbits with a synthetic peptide (CEGLKDEEKRLRR-SA) corresponding to amino-acid residues 55-68 of human STK38 and was purified by peptide affinity chromatography. Anti-SEK1/MKK4, anti-phospho SEK1/MKK4 (Thr261), antistress-activated protein kinase/JNK, anti-phospho stress-activated protein kinase/JNK (Thr183/Tyr185), anti-p38, anti-phospho p38 (Thr180/Tyr182), anti-MEK1, anti-MKK7, anti-phospho MKK7 (Ser271/Thr275) and anti-MKK3 antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-V5, anti-HA and anti-S antibodies were from MBL (Nagoya, Japan). Anti-Xpress and anti-Bcl-2 antibodies were from Invitrogen (Carlsbad, CA, USA) and BD Bioscience Pharmingen (San Diego, CA, USA), respectively. Anti-FLAG (M2), anti-phospho-MKK3/6 (Ser189/207) and antib-actin antibodies were from Sigma. Anti-MEKK1, anti-MEKK2 and anti-Sp1 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-MEKK2 antibody was from Epitomics (Burlingame, CA, USA).
Western blotting analysis
The cells were washed twice with ice-cold phosphate-buffered saline, and the cell pellets were lysed with standard SDS-PAGE Inhibition of MEKK1/2 by STK38sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% sodium laurylsulfate, 10% glycerol, 2.5% b-mercaptoethanol, 0.01% bromophenol blue, 0.005% crystal violet). Western blotting analyses were performed as described previously (Enomoto et al., 2003) .
Immunoprecipitation and immune complex kinase assays Cells were washed in ice-cold phosphate-buffered saline, and then lysed in lysis buffer containing 10 mM Tris-HCl (pH 7.7), 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA and protease inhibitor mixture (Roche). After centrifugation, the supernatants were incubated with a specific antibody and then mixed with protein A/G agarose. For binding assays, immune complexes were washed three times with lysis buffer, and subjected to western blotting analysis. For immune complex kinase assays, the immunoprecipitates were rinsed three times with lysis buffer and then twice with kinase buffer (12.5 mM Tris-HCl, pH 7.5, 0.025 mM EGTA, 0.025% b-mercaptoethanol, 0.05 mM sodium orthovanadate, 125 mM ATP, 18.75 mM magnesium chloride). For MEKK1/2 kinase assay, the immunoprecipitates were incubated with GST-tagged SEK1 (K129R) in kinase buffer containing 10 m Ci ml À1 [g-32 P]ATP at 301C for 15 min. For the analysis of MEKK2 autophosphorylation assay, GST-MEKK2 was incubated with immunopurified STK38 or STK38 (K118A) in kinase buffer containing 10 m Ci ml À1 [g-32 P]ATP at 301C for 15 min. The kinase reaction products were subjected to SDS-PAGE and analysed with a phosphoimaging device (BAS-2000; Fuji) . For STK38 kinase assay, synthetic peptides (KKRNRRLSVA) were incubated with immunopurified wild-type STK38 or STK38 (K118A) in kinase buffer containing 10 m Ci ml
À1
[g-32 P]ATP at 301C for 1 h. The kinase reaction products were spotted onto P81 paper disks (Whatman). The disks were washed three times in 1% phosphoric acid before being counted in a liquid scintillation counter.
Plasmid constructions
The open reading frames of mouse STK38, JNK1, SEK1 and MEKK2 were amplified by PCR with reverse transcription using mouse brain total RNA (BD Bioscience) and subcloned into pcDNA3.1-V5, pcDNA4.0-Xpress (Invitrogen), pFLAG-CMV2 (Kodak, Rochester, NY, USA) or pcDNA3-FLAG mammalian expression vectors, respectively. The expression vector for FLAG-tagged MEKK1 was constructed as described (Ito et al., 1999) . The amino-terminal region (residues 1-640) of MEKK1 was amplified by PCR and subcloned into pcDNA3-FLAG to generate pcDNA3-FLAG MEKK1N. The region encoding residues 1169-1488 of MEKK1 was amplified by PCR and subcloned into the pEF-HA to generate pEF-HA-DMEKK1. The carboxy-terminal regions (residues 342-619 and 425-619) of MEKK2 were amplified by PCR and subcloned into the pcDNA4/His Max expression vector, respectively. The region encoding residues 87-465 of STK38 was amplified by PCR and subcloned into pcDNA3.1-V5 to generate pcDNA3.1DN STK38-V5. To generate expression vectors for STK38 (K118A), MEKK2 (K385M) or SEK1 (K129R), site-directed mutagenesis was performed using overlapping PCR methods. The sequences of the open reading frames in the constructed plasmids were confirmed by DNA sequencing.
STK38 small interfering RNA The pcPURU6bicassette mammalian expression vector (iGene Therapeutics, Tsukuba, Japan) was used for expression of STK38 small interfering RNA. We purchased synthetic oligonucleotides targeting human STK38 (Takara Bio, Ohtsu, Japan), in which sense and antisense nucleotides were connected by an 11-base hairpin loop and formed a single chain. After annealing, the DNA fragments were ligated into the BspMI sites of the pcPURU6bicassette vector. The target sequence was as follows (only the antisense sequence is shown): 5 0 -AACAAG ACTTGGATTGGAA-3 0 . HeLa cells were transfected with the control or stk38-specific shRNA expression vector using FuGENE HD (Roche). At 24 h after transfection, the medium was replaced with fresh medium containing 0.2 mg ml À1 puromycin (InvivoGen, San Diego, CA, USA) for selection of the transformants. Following an additional incubation for 48 h, the cells were treated with various agents, such as 0.2 M sorbitol, and harvested immediately for western blotting analysis.
DNA microarray
Total RNA was prepared from cells using the Ultraspec RNA Isolation System (Biotecx Lab, Houston, TX, USA). Doublestranded cDNA was synthesized from total RNA with a SuperScript Double-Stranded cDNA Synthesis kit (Invitrogen). Biotinylated cRNA was prepared by in vitro transcription using a BioArray High Yield RNA Transcript Labeling kit (Enzo, Farmingdale, NY, USA) and then fragmented. For hybridization, the fragmented cRNA was added to a CodeLink Uniset Human 20 K I Bioarray (GE Healthcare, Farmingdale, NY, USA) for 18 h at 37 1C. The bioarrays were stained with Cy5-streptavadin (GE Healthcare, Farmingdale, NY, USA) and scanned using a Gene Pix 4000B scanner (Axon Instruments, Foster City, CA, USA). The spot signals were quantified with ImaGene 5.5 software (BioDiscovery, San Diego, CA, USA).
